Coming soon
Axen BRCA
Inherited (germline) testing of BRCA1 and BRCA2, the two genes most often examined for hereditary breast and ovarian cancer risk.
Prebooking opens soon
Decode the biology. Inform the decision.
Genomic testing for cancer, now coming to Pakistan. We read the tumour’s DNA to find changes your oncologist can act on.
No payment. No commitment. We will contact you when prebooking opens.
- EGFR
- KRAS
- BRAF
- ALK
- ROS1
- RET
- BRCA1
- BRCA2
- TP53
- PIK3CA
- PTEN
- ERBB2
- MET
- NTRK1
- IDH1
- ESR1
- KIT
- APC
- MLH1
- MSH2
- ATM
- PALB2
- CDK4
- FGFR2
How it works
From sample to answer, in four steps.
- 01
Sample
A small piece of tumour, or a blood draw.
- 02
Read
A machine reads the DNA, letter by letter.
- 03
Spot
Software flags changes linked to the cancer.
- 04
Explain
Your oncologist goes through the report with you.
A test adds information. Your oncologist decides what it means for treatment.
What brings you here today?
- I am an oncologistSee when NGS may matter, how requests work and what a structured report looks like.For oncologists
- A doctor suggested genomic testingA plain-language guide to what NGS is, what happens to the sample and what to ask your doctor.Read the patient guide
- I want to be first to bookPrebooking opens soon. Join the priority list and we will contact you. No payment, no commitment.Join the prebooking list
Testing
Five panels. One clear way to choose.
Five NGS panels, from a focused 88-gene panel to comprehensive profiling, for tumour tissue, blood (liquid biopsy) and inherited risk. Which panel fits depends on the cancer and the clinical question, and is decided with the treating oncologist.
- Coming soon
Axen Cancer Panel 1, FFPE tissue
A focused 88-gene tumour panel run on preserved (FFPE) tumour tissue, with fusion detection for ALK, RET and ROS1.
- Coming soon
Axen Cancer Panel 1, cfDNA (liquid biopsy)
The same 88-gene panel run on cell-free DNA from a blood sample, for when tissue is limited or unavailable.
- Coming soon
Comprehensive Cancer Panel, FFPE tissue
A broad tumour-tissue panel covering hundreds of cancer-related genes, for questions that a focused panel cannot answer.
- Coming soon
TruSight Oncology 500 (DNA)
A comprehensive 523-gene DNA assay for solid tumours, including copy-number analysis, tumour mutational burden and microsatellite instability.
Not sure which panel applies? Join the prebooking list and describe the clinical question. Price, turnaround and sample requirements are confirmed when you enquire.
Trust & quality
Built so you can check our work.
Genomic testing only helps if the result can be trusted. These are the safeguards behind each report.
- CAP · CLIA
Accredited laboratory
Sequencing is performed at a laboratory accredited by the College of American Pathologists (CAP) and certified under CLIA.
- QC metrics
Quality shown in every report
Reports include run quality metrics such as Q30, mean depth, coverage and uniformity, so a clinician can judge whether the result is reliable.
- AMP · ASCO · CAP
Evidence-tiered findings
Variants are checked against public databases such as ClinVar, and comprehensive reports use AMP/ASCO/CAP evidence tiers.
- Clinician-led
Oncologist first
Results are meant to be discussed with the treating oncologist. We do not recommend treatments and we do not replace clinical judgment.
- Consent-based
Your data, with consent
We collect only what is needed to reach you, never ask for a national ID number on this site, and explain sample shipping and data handling before anything is sent.
- Plan 9 · PITB
Backed locally
MedXplorer360 is a Pakistan-based oncology access company, backed by Plan 9 at the Punjab Information Technology Board.
For oncologists
Built around the clinical question.
You decide whether and what to test. We help with the logistics, the report and the evidence around it.
- 01Identify patients who may benefit from genomic testing
- 02Select an appropriate testing approach
- 03Receive structured genomic reports
- 04Review clinically relevant findings
- 05Access supporting evidence
- 06Integrate results into multidisciplinary decision-making
On the roadmap
- PlannedOnline test ordering
- PlannedPatient and sample tracking
- PlannedDigital reports
- PlannedVariant interpretation
- PlannedEvidence links
- PlannedMolecular tumor board support
These features are not live yet. Prebooking opens soon; requests will be handled by our team directly at first.
For patients and families
Genetic testing can be complicated. Getting started shouldn’t be.
- What is NGS?
- A lab method that reads many genes at once to find changes in a tumour.
- Why would my doctor suggest it?
- Some cancers carry changes that help doctors plan care.
- What happens to my sample?
- It is labelled, sent to the lab and checked for the genes in your test.
- What does the report say?
- Which changes were found and the evidence behind them. Finding nothing is a valid result.
- Who explains it?
- Your oncologist. Never change treatment without speaking to your doctor.
The report
What a structured genomic report looks like.
A demonstration of the layout we are building towards. Every value below is fictional.
Genomic report
DNA by MedXplorer360- Report ID
- DEMO-0000
- Sample type
- FFPE tumour tissue (illustrative)
- Test
- Targeted NGS panel (illustrative)
- Diagnosis
- Non-small cell lung cancer (illustrative)
- Tumour content
- Not applicable (demo)
| Gene | Variant | Classification | Evidence level | Clinical relevance | Potential therapeutic association | References |
|---|---|---|---|---|---|---|
| EGFR | p.Leu858Arg | Pathogenic | Tier I · Level A | Predictive | EGFR-directed therapy class | Linked in live reports |
| TP53 | p.Arg273His | Pathogenic | Tier III | Prognostic context | No direct association | Linked in live reports |
| ARID1A | p.Gln1084* | Likely pathogenic | Tier III | Under investigation | No established association | Linked in live reports |
Illustrative layout only. Variants, classifications and evidence levels shown here are fictional and are not clinical guidance. In a live report each finding links to its supporting references.
Evidence & science
Evidence matters.
A variant is only as useful as the evidence behind it. Findings should be interpreted against appropriate scientific and clinical evidence, and the weight of that evidence differs by cancer type and clinical context.
- Clinical guidelines
Recommendations from professional and clinical bodies on when and how to test and act on results.
- Regulatory information
Approved indications and labelling for therapies, where they are tied to a molecular finding.
- Peer-reviewed literature
Published studies describing the biology and clinical significance of a variant.
- Clinical trials
Registered studies that may be relevant to a finding. Eligibility is determined by the study team.
- Curated genomic databases
Structured, regularly updated collections of variant annotations and classifications.
Clinical guidelines
Your oncologist decides. Guidelines inform.
Whether and which genomic test is appropriate depends on cancer type, stage and treatment history, and is a decision for the treating oncologist with reference to current clinical guidelines. We point you to the source rather than paraphrase it.
For clinicians
NCCN Clinical Practice Guidelines in Oncology are the reference many oncologists use when deciding which biomarkers to test for a given cancer type. Read the current version for your patient's diagnosis directly from NCCN.
For patients and families
NCCN Guidelines for Patients explain cancer care in plain language and include questions to bring to your appointment. They are free from NCCN.
NCCN® and NCCN Guidelines® are trademarks of the National Comprehensive Cancer Network, Inc. DNA by MedXplorer360 is not affiliated with, sponsored or endorsed by NCCN. NCCN does not endorse any specific commercial assay. Guideline content is not reproduced on this site; always consult the current version at nccn.org. Guidelines do not replace independent medical judgment for an individual patient.
Genomic testing in Pakistan
Genomic testing access, built for Pakistan.
DNA by MedXplorer360 is being built to make NGS cancer testing and tumor profiling easier to reach for oncologists and patients in Pakistan. Requests are welcome from across the country, from Islamabad and Rawalpindi to Lahore, Karachi, Peshawar and beyond.
How samples are collected and shipped, and where analysis takes place, will be stated clearly for each test.
Questions
Frequently asked questions.
Is NGS testing for cancer available in Pakistan?
DNA by MedXplorer360 is being built to make NGS cancer testing easier to access in Pakistan. Prebooking opens soon. Join the priority list and we will contact you when it opens. Five panels are planned for launch: Axen BRCA, Axen Cancer Panel 1 (FFPE tissue and cfDNA liquid biopsy), a comprehensive FFPE tissue panel and TruSight Oncology 500 (DNA). Sample requirements and timelines are confirmed when you enquire.
How much does NGS testing cost in Pakistan?
Pricing depends on the panel. Contact us on WhatsApp for the current price of each panel; we do not publish estimates that may be out of date. Joining the prebooking list is free and involves no payment.
Can I send a sample from another city?
Requests are welcome from across Pakistan. How samples are collected and shipped will be explained for each test when your request is accepted.
What is NGS?
Next-generation sequencing (NGS) is a laboratory technology that reads many DNA fragments in parallel. In oncology it is used to look at selected genes, or larger parts of the genome, for changes (variants) that may be relevant to a person's cancer.
What is genomic testing?
Genomic testing looks for changes in a person's DNA or in a tumour's DNA. In cancer care it can describe molecular features of a tumour, or identify inherited variants, depending on the test chosen and the sample used.
Why might an oncologist recommend NGS?
Some cancers contain molecular alterations that are relevant to diagnosis, prognosis or treatment selection, and guidelines recommend molecular testing in certain situations. Whether NGS is appropriate depends on the cancer type, stage, previous treatment and the specific clinical question. That is a decision for the treating oncologist.
Is NGS the same as genetic testing?
NGS is a technology; genetic testing is the purpose. Many genetic tests use NGS, but not all do. Tumour (somatic) testing and inherited (germline) testing answer different questions and may use different samples.
What samples can be used?
It depends on the test. Common sample types in oncology include tumour tissue and blood, but the accepted sample, quantity and handling requirements are specific to each test. These are listed per test and confirmed before a sample is collected.
How long does testing take?
Turnaround time depends on the test and on sample logistics. Each test page will state an approximate turnaround once confirmed, and our team will confirm the expected timeline when a request is accepted.
What does a genomic report contain?
A report typically summarises the sample and test performed, the variants detected, how each variant is classified, and the evidence that supports its clinical relevance. See the demonstration report on this page, which uses fictional data only.
Does a genomic result guarantee a specific treatment?
No. A result may add information to a clinical discussion, but it does not guarantee a treatment option, a response to treatment or an outcome. Many tests return no finding that changes management. Treatment decisions are made by the treating oncologist with the patient.
Who should interpret my result?
Your treating oncologist, who knows your full clinical picture. Some results, particularly inherited findings, may also warrant genetic counselling. Please do not change or stop any treatment based on a report without speaking to your doctor.
Can patients order testing themselves?
Genomic testing in oncology should be guided by a treating doctor. Patients are welcome to contact our team to understand the process, and we will work with the patient's doctor to arrange a request where appropriate.
Prebooking opens soon
Be first in line when prebooking opens.
Have a patient who may need genomic testing? Join the priority list and tell us the clinical question. We will contact you when prebooking opens. Joining is free, takes no payment and is not a test order; testing proceeds with the treating doctor’s involvement.